Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
1394 studies found for:    Doxorubicin (liposomal) OR Doxil[TREATMENT] AND HIV [CONDITION]
Show Display Options
Rank Status Study
21 Completed Liposomal Doxorubicin in Treating Patients With Prostate Cancer
Condition: Prostate Cancer
Intervention: Drug: pegylated liposomal doxorubicin hydrochloride
22 Completed Pegylated Liposomal Doxorubicine and Prolonged Temozolomide in Addition to Radiotherapy in Newly Diagnosed Glioblastoma
Condition: Glioblastoma
Intervention: Drug: Pegylated Liposomal Doxorubicine
23 Completed
Has Results
Doxorubicin HCI Liposome Injection Versus Weekly Docetaxel in Patients First Relapse Metastatic Breast Cancer
Condition: Breast Cancer
Interventions: Drug: Liposomal Doxorubicin;   Drug: Docetaxel
24 Active, not recruiting Assess Bioequivalence of Two Formulations of Doxorubicin Hydrochloride Liposome in Female Patients With Ovarian Cancer
Condition: Ovarian Cancer
Intervention: Drug: Doxorubicin hydrochloride liposome
25 Completed
Has Results
Liposomal Doxorubicin Before Mastectomy in Treating Women With Invasive Breast Cancer
Condition: Breast Cancer
Interventions: Drug: Intraductal arm;   Drug: Intravenous arm
26 Terminated Phase I/II Open-Label, Dose Escalation Study To Determine The Maximum Tolerated Dose And To Evaluate The Safety Profile of Lenalidomide (Revlimid® CC-5013) With Liposomal Doxorubicin In Subjects With Advanced Ovarian and Primary Peritoneal Carcinoma
Condition: Ovarian Cancer
Interventions: Drug: CC-5013;   Drug: liposomal doxorubicin
27 Completed Dose-Escalation Study of LY573636-sodium and Liposomal Doxorubicin in Patients With Advanced Solid Tumors
Condition: Solid Tumors
Interventions: Drug: LY573636;   Drug: Liposomal Doxorubicin
28 Terminated
Has Results
Study of Pazopanib and Doxil in Patients With Advanced Relapsed Platinum-Sensitive or Platinum-Resistant Ovarian, Fallopian Tube or Primary Peritoneal Adenocarcinoma
Conditions: Ovarian Cancer;   Fallopian Tube Cancer;   Peritoneal Carcinoma
Interventions: Drug: Pazopanib;   Drug: Doxil
29 Recruiting Pomalidomide in Combination With Liposomal Doxorubicin in People With Advanced or Refractory Kaposi Sarcoma
Condition: Kaposi Sarcoma
Interventions: Drug: liposomal doxorubicin;   Drug: pomalidomide
30 Recruiting Phase Ib Study of Anetumab Ravtansine in Combination With Pegylated Liposomal Doxorubicin in Patients With Recurrent Mesothelin-expressing Platinum-resistant Cancer
Condition: Ovarian Neoplasms
Interventions: Drug: Anetumab ravtansine (BAY94-9343);   Drug: Pegylated Liposomal Doxorubicin
31 Completed Phase I Study of DOXIL and Temsirolimus in Resistant Solid Malignancies
Condition: Resistant Solid Malignancies
Interventions: Drug: Temsirolimus;   Drug: Pegylated liposomal doxorubicin
32 Active, not recruiting Retrospective Study to Analyze the Efficacy and Safety of Trabectedin and Pegylated Liposomal Doxorubicin (PLD ) in the Treatment of Patients With Platinum-sensitive Recurrent Ovarian Cancer (ROC), According to SmPC
Condition: Ovarian Epithelial Cancer Recurrent
Intervention: Drug: Trabectedin and Pegylated Liposomal Doxorubicin
33 Unknown  EGEN-001 and Pegylated Liposomal Doxorubicin Hydrochloride in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
Conditions: Ovarian Clear Cell Cystadenocarcinoma;   Ovarian Endometrioid Adenocarcinoma;   Ovarian Mixed Epithelial Carcinoma;   Ovarian Serous Cystadenocarcinoma;   Ovarian Undifferentiated Adenocarcinoma;   Recurrent Fallopian Tube Cancer;   Recurrent Ovarian Epithelial Cancer;   Recurrent Primary Peritoneal Cavity Cancer
Interventions: Biological: EGEN-001;   Drug: pegylated liposomal doxorubicin hydrochloride;   Other: laboratory biomarker analysis
34 Active, not recruiting Bortezomib and Pegylated Liposomal Doxorubicin Hydrochloride in Treating Patients With Previously Untreated Symptomatic Multiple Myeloma
Conditions: DS Stage I Plasma Cell Myeloma;   DS Stage II Plasma Cell Myeloma;   DS Stage III Plasma Cell Myeloma
Interventions: Drug: Bortezomib;   Other: Laboratory Biomarker Analysis;   Drug: Pegylated Liposomal Doxorubicin Hydrochloride
35 Recruiting Effects of STM 434 Alone or in Combination With Liposomal Doxorubicin in Patients With Ovarian Cancer or Other Advanced Solid Tumors
Conditions: Ovarian Cancer;   Fallopian Tube Cancer;   Endometrial Cancer;   Solid Tumors
Interventions: Drug: STM 434;   Drug: Liposomal doxorubicin
36 Completed
Has Results
Ixabepilone and Liposomal Doxorubicin in Advanced Ovarian Cancer
Conditions: Fallopian Tube Cancer;   Female Reproductive Cancer;   Recurrent Breast Cancer;   Recurrent Ovarian Epithelial Cancer;   Stage III Ovarian Epithelial Cancer;   Stage IV Breast Cancer;   Stage IV Ovarian Epithelial Cancer
Interventions: Drug: ixabepilone;   Drug: pegylated liposomal doxorubicin hydrochloride
37 Not yet recruiting HIFU Hyperthermia With Liposomal Doxorubicin (DOXIL) for Relapsed or Refractory Pediatric and Young Adult Solid Tumors
Conditions: Rhabdomyosarcoma;   Neuroblastoma;   Sarcoma;   Sarcoma, Ewing;   Osteosarcoma
Interventions: Drug: Doxorubicin HCl liposomal injection;   Device: Philips Sonalleve MR-HIFU Hyperthermia
38 Completed A Study of DOX-SL in the Treatment of AIDS-Related Kaposi's Sarcoma
Conditions: Sarcoma, Kaposi;   HIV Infections
Intervention: Drug: Doxorubicin hydrochloride (liposomal)
39 Completed Trial of Liposomal Doxorubicin (Doxil) and Weekly Docetaxel (Taxotere)
Conditions: Cancer;   Carcinoma
Intervention: Drug: liposomal doxorubicin and docetaxel
40 Active, not recruiting Veliparib and Pegylated Liposomal Doxorubicin Hydrochloride in Treating Patients With Recurrent Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer or Metastatic Breast Cancer
Conditions: Estrogen Receptor Negative;   HER2/Neu Negative;   Male Breast Carcinoma;   Progesterone Receptor Negative;   Recurrent Breast Carcinoma;   Recurrent Fallopian Tube Carcinoma;   Recurrent Ovarian Carcinoma;   Recurrent Primary Peritoneal Carcinoma;   Stage IV Breast Cancer;   Triple-Negative Breast Carcinoma
Interventions: Other: Laboratory Biomarker Analysis;   Drug: Pegylated Liposomal Doxorubicin Hydrochloride;   Other: Pharmacological Study;   Drug: Veliparib

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.